Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud
Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Richard Greil(Paracelsus Medical University), Nicole C.C. Them(Austrian Academy of Sciences), Sarita Ban(Donauspital), Pavla Kadlecová, Dominik Wolf(Universität Innsbruck), Ella Willenbacher(Innsbruck Medical University), Michael Zörer(AOP Orphan (Austria)), Alexander Egle(Paracelsus Medical University), Oleh Zagrijtschuk(AOP Orphan (Austria)), Heinz Gisslinger(Medical University of Vienna), Martin Schalling(Karolinska University Hospital), Christoph Klade(Intercell (Austria)), Bettina Gisslinger(Medical University of Vienna), Thomas Melchardt(Paracelsus Medical University), Oliver Ammann-Mwathi(AOP Orphan (Austria)), Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Ernst Schlögl(Hanusch Hospital), Günther Gastl(Innsbruck Medical University), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Maria Theresa Krauth(Medical University of Vienna), Róbert Královics(Medical University of Vienna)
Cited by 1
Related Papers
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Bim is a suppressor of Myc-induced mouse B cell leukemia
|Proceedings of the National Academy of Sciences|2004|482
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450